摘要
目的 探讨左旋多巴联合普拉克索治疗帕金森病患者的临床疗效及其对患者运动功能的影响。方法 选取本院2018年4月至2022年4月临床收治的96例帕金森患者作为研究对象,其中48例患者服用左旋多巴治疗,作为对照组;予以另48例患者左旋多巴联合普拉克索治疗,作为观察组。两组患者持续治疗12周,观察不同治疗方案对患者UPDRS、HAMD、HAMA评分的影响,同时记录评估两组患者药物治疗的安全性。结果 治疗前两组患者UPDRSⅡ、UPDRSⅢ评分的基线资料对比(P> 0.05);治疗后观察组UPDRSⅡ、UPDRSⅢ评分低于对照组(P <0.05)。治疗前两组患者HAMD、HAMA评分基线资料对比(P> 0.05);治疗后观察组HAMD、HAMA评分低于对照组(P <0.05)。两组患者药物不良反应发生率总体相当,对比差异无统计学意义(P> 0.05)。结论 左旋多巴联合普拉克索治疗帕金森病的疗效较好,对患者日常生活、运动能力均有明显的促进作用,同时还有利于改善患者的情绪状态,其次本治疗方案的药物安全性能够保障。
Objective To investigate the clinical efficacy of levodopa combined with pramipexole in the treatment of Parkinson’s disease and its influence on motor function. Methods Ninety-six patients with parkinson’s disease in our hospital from April 2018 to April 2022 were selected as the research objects, 48 patients were treated with levodopa as the control group, and the other 48 patients were treated with levodopa combined with pramipexole as the observation group. The patients in the two groups were treated for 12 weeks. The effects of different treatment schemes on the Unified Parkinson’s Comprehensive Disease Rating scale(UPDRS), Hamilton Depression Scale(HAMD) and Hamilton Anxiety Scale(HAMA) were observed, and the safety of drug treatment in the two groups was recorded and evaluated. Results Before treatment, the baseline data of UPDRSⅡ and UPDRSⅢ scores of the two groups were compared(P>0.05);after treatment, the UPDRSⅡ and UPDRSⅢ scores of the observation group were lower than those of the control group(P<0.05). Before treatment, the baseline data of HAMD and HAMA scores of the two groups were compared(P>0.05);after treatment, the HAMD and HAMA scores of the observation group were lower than those of the control group(P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05). Conclusion Levodopa combined with pramipexole has a good effect in the treatment of Parkinson’s disease, which can significantly promote the daily life and motor ability of patients, and also help to improve the emotional state of patients. Secondly, the drug safety of this treatment scheme can be guaranteed, which is worthy of application and promotion.
作者
雷爱弟
LEI Aidi(Department of Neurology,Xiamen Fifth Hospital,Xiamen 361100,China)
出处
《中国医药指南》
2023年第4期84-86,共3页
Guide of China Medicine
